Literature DB >> 12124797

Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression.

Khalid Bajou1, Jean-Marc Lewalle, Christian Rodriguez Martinez, Claudine Soria, He Lu, Agnès Noël, Jean-Michel Foidart.   

Abstract

During angiogenesis, endothelial cells use uPA and PAI-1 to migrate and degrade the basement membrane surrounding capillary blood vessels. Invasive tumor cells produce a large amount of uPA that could bind uPAR present at the endothelial cell surface to facilitate their invasion. To verify this hypothesis, endothelial cells were incubated with conditioned medium (CM) from two breast cancer cell lines (MCF7 and MDA MB 231 cells). Within a short incubation period (30 min) with both CM, an increase of uPA, PAI-1 and uPA-PAI-1 complex was detected in endothelial cell layer as assessed by casein zymography, ELISA and uPA immunostaining. The extent of this enhancement was related to the levels of uPA secreted by tumor cells (high in MDA MB 231 cells and low in MCF7 cells). After 2 hr of incubation, the CM from both tumor cells upregulated uPA and PAI-1 mRNA levels in endothelial cells in a time-dependent manner. The uPA increase in the cell layer could not be attributable to an increase of uPAR level. Only the CM from highly invasive MDA MB 231 cells increased the angiogenic morphotype of endothelial cells assessed in a collagen gel. A single addition of amino-terminal fragment of uPA (ATF) was able to abolish the angiogenic effect induced by MDA MB 231 cell CM. Our data demonstrate that the interactions occurring between breast tumor cells and endothelial cells can modulate tumor angiogenesis at least by two mechanisms: an increase of uPA and PAI-1 cell surface-binding and of their expression by endothelial cells. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124797     DOI: 10.1002/ijc.10487

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4.

Authors:  Chang Hyun Byon; Robert W Hardy; Changchun Ren; Selvarangan Ponnazhagan; Danny R Welch; Jay M McDonald; Yabing Chen
Journal:  Lab Invest       Date:  2009-09-14       Impact factor: 5.662

Review 2.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

3.  Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.

Authors:  Salvatore Ulisse; Enke Baldini; Marcella Mottolese; Steno Sentinelli; Patrizia Gargiulo; Brancato Valentina; Salvatore Sorrenti; Anna Di Benedetto; Enrico De Antoni; Massimino D'Armiento
Journal:  BMC Cancer       Date:  2010-04-19       Impact factor: 4.430

4.  Urokinase expression in course of benign and malignant mammary lesions: comparison between nodular and healthy tissues.

Authors:  Francesca Ceccarelli; Andrea Fuso; Liana Civitelli; Ersilia Ranieri; Giuliana Caprio; Paola Pagni; Mario Rengo; Sigfrido Scarpa
Journal:  J Cancer Res Clin Oncol       Date:  2009-10-14       Impact factor: 4.553

Review 5.  Platelets, coagulation and fibrinolysis in breast cancer progression.

Authors:  Inder Lal; Kim Dittus; Chris E Holmes
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

6.  Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1.

Authors:  Jennifer C Carter; Frank C Church
Journal:  PPAR Res       Date:  2009-08-06       Impact factor: 4.964

7.  ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling.

Authors:  Arindam Banerjee; Zheng-Sheng Wu; Peng-Xu Qian; Jian Kang; Dong-Xu Liu; Tao Zhu; Peter E Lobie
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.